Evidence map›Paper›PMID 26388872›Full record

ReviewFrontiers in immunology2015

MHC Class II-Restricted Epitopes Containing an Oxidoreductase Activity Prompt CD4(+) T Cells with Apoptosis-Inducing Properties.

Elin Malek Abrahimians, Vincent A Carlier, Luc Vander Elst, Jean-Marie R Saint-Remy

2 registry-linked trialsAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03272269 phase1completednot on this mapstarted 2017, after this paper: background citation

A Phase I Placebo-controlled, Double-blind, Dose Escalation Clinical Trial to Evaluate the Safety and Immune Responses of Imcyse's IMCY-0098 in Patients With Recent Onset Type 1 Diabetes

TypeinterventionalSponsorImcyse SARan2017 to 2019Enrolled41ConditionsType 1 Diabetes MellitusArmsIMCY-0098, Placebo
NCT05417269 phase1 / phase2unknown statusnot on this mapstarted 2022, after this paper: background citation

A Phase I/II Dose Escalation/Adaptive Design Study to Evaluate the Safety and Efficacy of IMCY-0141 in Patients With Relapsing Remitting-Multiple Sclerosis (RR-MS)

TypeinterventionalSponsorImcyse SARan2022 to 2025Enrolled150ConditionsMultiple Sclerosis, Relapsing-RemittingArmsIMCY-0141, Placebo, Dimethyl Fumarate
3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elin Malek AbrahimiansCenter for Molecular and Vascular Biology, University of Leuven , Leuven , Belgium ; ImCyse SA , Leuven , Belgium.
Vincent A CarlierCenter for Molecular and Vascular Biology, University of Leuven , Leuven , Belgium ; ImCyse SA , Leuven , Belgium.
Luc Vander ElstCenter for Molecular and Vascular Biology, University of Leuven , Leuven , Belgium ; ImCyse SA , Leuven , Belgium.
Jean-Marie R Saint-RemyCenter for Molecular and Vascular Biology, University of Leuven , Leuven , Belgium ; ImCyse SA , Leuven , Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abrogating an unwanted immune response toward a specific antigen without compromising the entire immune system is a hoped-for goal in immunotherapy. Instead of manipulating dendritic cells and suppressive regulatory T cells, depleting effector T cells or blocking their co-stimulatory pathways, we describe a method to specifically inhibit the presentation of an antigen eliciting an unwanted immune reaction. Inclusion of an oxidoreductase motif within the flanking residues of MHC class II epitopes polarizes CD4(+) T cells to cytolytic cells capable of inducing apoptosis in antigen presenting cells (APCs) displaying cognate peptides through MHC class II molecules. This novel function results from an increased synapse formation between both cells. Moreover, these cells eliminate by apoptosis bystander CD4(+) T cells activated at the surface of the APC. We hypothesize that they would thereby block the recruitment of cells of alternative specificity for the same autoantigen or cells specific for another antigen associated with the pathology, providing a system by which response against multiple antigens linked with the same disease can be suppressed. These findings open the way toward a novel form of antigen-specific immunosuppression.

Indexed as

apoptosiscytolytic CD4+ T cellsimmune suppressionMHC class II epitopesoxidoreductase activity

Identifiers

PMID26388872
PMCPMC4556975

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.